相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Review on the clinical use of eribulin mesylate for the treatment of breast cancer
Olexiy Aseyev et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Chemotherapy options for patients suffering from heavily pretreated metastatic breast cancer
Guy Jerusalem et al.
FUTURE ONCOLOGY (2015)
Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Peter A. Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: Randomized phase II multicenter trial
Sung-Bae Kim et al.
INVESTIGATIONAL NEW DRUGS (2014)
Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer
John P. Crown et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer
A. G. Pallis et al.
ANNALS OF ONCOLOGY (2012)
Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Treatment of metastatic breast cancer: second line and beyond
H. Roche et al.
ANNALS OF ONCOLOGY (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
Adam M. Brufsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortes et al.
LANCET (2011)
Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review
Linda J. M. Oostendorp et al.
LANCET ONCOLOGY (2011)
Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy
Mark Clemons et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Joseph A. Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Anthracycline- and/or Taxane-Resistant Breast Cancer: Results of a Literature Review to Determine the Clinical Challenges and Current Treatment Trends
Alvaro Moreno-Aspitia et al.
CLINICAL THERAPEUTICS (2009)
The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: A systematic review
Jacek Jassem et al.
EUROPEAN JOURNAL OF CANCER (2009)
Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study
Joseph A. Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
David Cameron et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
Miguel Martin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
Eva S. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The impact of new chemotherapeutic and agents on survival in a population-based of women with metastatic breast cancer hormone cohort
Stephen K. Chia et al.
CANCER (2007)
Investigation of tumor biomarkers as response predictors in a monotherapy study with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cancer
H. L. Gomez et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes:: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial
Miguel Martin et al.
LANCET ONCOLOGY (2007)
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28
EP Mamounas et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Heterogeneity testing in meta-analysis of genome searches
E Zintzaras et al.
GENETIC EPIDEMIOLOGY (2005)
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
KD Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer
P Fumoleau et al.
EUROPEAN JOURNAL OF CANCER (2004)
Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin
A Venturino et al.
BREAST CANCER RESEARCH AND TREATMENT (2000)
分享论文
